Yousif Capital Management LLC Decreases Stock Holdings in Masimo Co. (NASDAQ:MASI)

Yousif Capital Management LLC lessened its stake in Masimo Co. (NASDAQ:MASI) by 2.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,786 shares of the medical equipment provider’s stock after selling 369 shares during the quarter. Yousif Capital Management LLC’s holdings in Masimo were worth $2,630,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Jones Financial Companies Lllp purchased a new stake in Masimo during the 4th quarter worth approximately $27,000. Farther Finance Advisors LLC grew its holdings in shares of Masimo by 128.9% during the first quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 116 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Masimo by 40.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 64 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in Masimo by 31.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 60 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of Masimo in the fourth quarter valued at approximately $46,000. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have commented on MASI shares. Wells Fargo & Company reduced their target price on shares of Masimo from $205.00 to $190.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 7th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research report on Thursday, April 10th. Raymond James decreased their price target on Masimo from $204.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. Wall Street Zen downgraded Masimo from a “buy” rating to a “hold” rating in a research report on Friday, May 30th. Finally, BTIG Research set a $193.00 price objective on shares of Masimo and gave the company a “buy” rating in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Masimo currently has an average rating of “Moderate Buy” and an average target price of $191.60.

Masimo Stock Down 2.5%

Shares of Masimo stock opened at $161.20 on Friday. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $194.88. The company has a 50 day moving average of $158.44 and a 200 day moving average of $167.11. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $8.74 billion, a P/E ratio of 111.17 and a beta of 1.19.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.24 by $0.12. The firm had revenue of $372.00 million during the quarter, compared to the consensus estimate of $367.79 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company’s revenue was down 24.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.77 earnings per share. As a group, research analysts forecast that Masimo Co. will post 4.1 EPS for the current fiscal year.

Insider Transactions at Masimo

In related news, COO Bilal Muhsin sold 10,000 shares of the business’s stock in a transaction on Monday, May 12th. The shares were sold at an average price of $163.28, for a total value of $1,632,800.00. Following the completion of the sale, the chief operating officer now directly owns 24,172 shares of the company’s stock, valued at $3,946,804.16. The trade was a 29.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 16.90% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.